Loading...
Loading...
Achillion Pharmaceuticals,
Inc.
ACHN today announced that the U.S. Patent & Trademark Office has
granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter
and method of use claims for ACH-3102 and structurally related NS5A inhibitor
compounds. ACH-3102 is Achillion's second generation Phase 2 NS5A inhibitor
being investigated for the treatment of chronic hepatitis C virus (HCV)
infection. This patent is entitled "Substituted aliphanes, cyclophanes,
heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for
treating HCV infections," and provides a patent term which lasts until 2032.
"We believe that this key patent grant will provide another important anchor
for Achillion's intellectual property portfolio. With the issuance of this
patent for our differentiated NS5A inhibitor, ACH-3102, along with the
previously granted patent for sovaprevir, our NS3/4A protease inhibitor, we
are pleased to recognize the talented Achillion team that discovered and has
advanced these compounds into Phase 2 trials evaluating their use in all-oral
combination regimens for the treatment of chronic HCV," commented Milind
Deshpande, President and Chief Executive Officer of Achillion.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in